Watch a Reconstructed 250-Year-Old Robotic Painting Bring a Fiery Mount Vesuvius Back to Life
So much so that in 1775 he designed a rotating device that, with mechanical movement and light, could bring to life the fiery magma depicted in Pietro Fabris' 1771 watercolor, 'Night view of a current of lava.' While experts aren't sure if Hamilton ever advanced the multimedia device beyond the design phase, the preservation of its detailed sketch at the Bordeaux Municipal Library has allowed engineering students in Australia to reconstruct it 250 years later.
Footprints Reveal Ancient Escape From Vesuvius—1,800 Years Before Pompeii's Destruction
Based on a University of Melbourne video, the reconstruction consists of a perforated tube rotating around a source of light, casting moving splotches of brightness on the back of the watercolor painting. The light shines through the canvas so that people regarding the artwork from the front see the light streaming along the painted lava, as if it were really moving.
'It is a wonderful piece of science communication. People around the world have always been fascinated by the immense power of volcanos,' Richard Gillespie, senior curator in the faculty of engineering and information technology at the University of Melbourne, said in a university statement.
The recreation is now the centerpiece of The Grand Tour, an exhibit at the University of Melbourne's Baillieu Library that explored the educational and touristic trip to Italy that many young British upper-class men undertook in the 18th century.
'I've always wanted to recreate the apparatus, and suddenly the opportunity of the exhibition on the Grand Tour at the Baillieu Library gave me the opportunity to, sort of, commission a team,' Gillespie explained in the video. 'They are trying to really use 21st-century mechatronics and techniques and electronics to recreate in the same spirit of Hamilton's originally clockwork-driven and candle-lit apparatus.'
Graduate students Xinyu (Jasmine) Xu and Yuji (Andy) Zeng built the device over three months, incorporating laser-cut timber and acrylic, electronic control systems, and programmable LED lighting.
Pompeii Family Blocked Bedroom Door With Bed to Escape Eruption, New Findings Reveal
'It was a fantastic way to build my hands-on problem-solving skills,' said Zeng. 'We still faced some of the challenges that Hamilton faced. The light had to be designed and balanced so the mechanisms were hidden from view.'
For those of you in Australia, The Grand Tour exhibition is slated to run until June 28, 2026, also showcasing objects related to Hamilton's time in Naples.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
12 hours ago
- Gizmodo
Was Jesus Really Wrapped in the Shroud of Turin? 3D Study Says Probably Not
The Shroud of Turin is an ancient linen cloth with the subtle impression of the front and back of a crucified man. While many believe it was the burial shroud in which Jesus was wrapped when he died in the 30s CE, scientific research has dated it to between 1260 and 1390 CE, suggesting it's a medieval artifact. An ingenious new approach using 3D scans is now adding further credence to the suggestion that Jesus's body—or any body for that matter—never touched this famous fabric. Cicero Moraes, a 3D designer specializing in digital 3D facial reconstruction, has joined the contentious debate by using computer models to simulate two scenarios: draping a sheet of fabric (the same size as the Shroud of Turin) on a 3D human and one on a low-relief depiction of a human to compare their imprints, or contact patterns. Low-reliefs, also known as bas-reliefs, are carvings in which the figures emerge only slightly from their backgrounds. In other words, Moraes wanted to see whether the figure on the Shroud of Turin corresponds more closely to the imprint of a human body or a bas-relief. 'The results demonstrate that the contact pattern generated by the low-relief model is more compatible with the Shroud's image, showing less anatomical distortion and greater fidelity to the observed contours, while the projection of a 3D body results in a significantly distorted image,' Moraes wrote in a study published late last month in the journal Archaeometry. Moraes is the sole author. Simply put, 'the Shroud's image is more consistent with an artistic low-relief representation than with the direct imprint of a real human body, supporting hypotheses of its origin as a medieval work of art.' The study paid particular attention to the 'Agamemnon Mask effect.' The effect sees the contact pattern of fabric draped over volume, like a body, appear distorted and bloated once flattened or pulled taut. The name comes from the famous Agamemnon Mask, a 3,500-year-old gold death mask Heinrich Schliemann (the amateur archaeologist best known for 'discovering' the city of Troy) unearthed in Greece and misidentified as belonging to the Homeric hero Agamemnon. The full-face mask, which represents the face of the deceased, appears strangely wide for the same reason that the imprint of a human face in fabric would also appear wide once flattened. The real Shroud of Turin does not display the Agamemnon Mask effect. On the other hand, 'the printed image, generated from the contact regions in low relief, shows high compatibility with that present on the Shroud of Turin, significantly corresponding to its contours, even considering a not entirely flat base,' Moraes explained in the study. This conclusion supports the theory that the Shroud was not wrapped around a real human (or divine) body. Instead, it may have been an artistic representation, he suggested, potentially related to funerary practices. 'This work not only offers another perspective on the origin of the Shroud of Turin's image but also highlights the potential of digital technologies to address or unravel historical mysteries,' he concludes, 'intertwining science, art, and technology in a collaborative and reflective search for answers.'
Medscape
15 hours ago
- Medscape
Tetanus Shots: Lifesavers or Overkill?
A review in the Clinical Microbiology Reviews highlighted the remarkable success of vaccines in nearly eliminating tetanus and diphtheria. Today, widespread immunization has made these diseases so rare that a person is up to 1000 times more likely to be struck by lightning than to develop either infection. In the US, tetanus occurs at a rate of less than one case per 10 million person-years, whereas diphtheria is even rarer, at approximately one case per billion person-years. In recent decades, nearly all deaths from these diseases have occurred in individuals who have not completed the primary vaccination series. The authors pointed out that the exceptionally rare deaths from tetanus or diphtheria 'are not due to vaccine failure and instead are mainly due to a failure to vaccinate.' Booster Debate Tetanus and diphtheria vaccines are unusual because many countries, including the US and Italy, recommend routine boosters in adults every 10 years — a policy not applied to any other childhood vaccine. However, the authors argued that these boosters were not necessary to maintain population-level immunity. They presented serologic, epidemiologic, and historical data showing that adult booster doses could be safely avoided with substantial cost savings. Mark K. Slifka, PhD, professor at Oregon Health & Science University (OHSU), Portland, Oregon, and senior scientist at the OHSU's Oregon National Primate Research Center, based in Hillsboro, Oregon, and colleagues emphasized that adult booster doses, which have already been phased out in several European countries, can be safely discontinued if high vaccination coverage in children is maintained and vaccines remain available for specific clinical needs. UK vs France A striking comparison between the UK and France supports the argument that adult booster vaccinations may be unnecessary. Both countries have similar population sizes and comparable pediatric vaccination schedules for tetanus and diphtheria, with five doses each compared with four in Italy, with coverage rates between 94% and 96%. The UK had never implemented routine boosters for adults, whereas France required boosters every 10 years until 2012. Since 2014, France has recommended boosters every 10 years for adults older than 65 years and every 20 years for younger adults at ages 25, 45, and 65 years. Despite these differing booster policies, disease incidence remains extremely low in both countries, with fewer than one tetanus case per 4 million person-years (0.21 vs 0.12 cases per million person-years in the UK and France, respectively) and fewer than one diphtheria case per 16 million person-years (0.06 vs 0.03 per million person-years in the UK and France, respectively). Notably, the incidence was slightly lower in the UK, where boosters were not administered to adults. A study of 30 high-income countries found no significant difference in tetanus or diphtheria rates between countries that administered boosters to both children and adults and those that administered boosters only to children. Eight countries did not offer adult tetanus boosters, and nine did not offer adult diphtheria boosters. Cost Savings The authors estimated that eliminating routine 10-yearly tetanus-diphtheria boosters in the US, in alignment with the World Health Organization (WHO) guidance, which has not recommended adult boosters since 2017, could save approximately $1 billion annually. In Europe, eight countries besides the UK do not schedule routine tetanus and diphtheria boosters: Spain (which stopped boosters in 2009 but offers a single dose around the age of 65 years), Croatia (one booster after the age of 60 years), Ireland, Iceland, Malta, the Netherlands, Poland, and Hungary. The WHO continues to recommend a tetanus and diphtheria booster during each pregnancy, administered as the diphtheria-tetanus-pertussis vaccine to protect newborns from whooping cough, as well as for travelers to diphtheria-endemic areas and for wound management in potential tetanus cases. Vaccination is also advised for individuals who are unvaccinated or whose immunization status is uncertain. Long-Term Immunity Why should routine booster shots be stopped for adults? This is because the antibodies last longer. Studies have shown that tetanus antibodies have a half-life of 11 years, whereas diphtheria antibodies have a half-life of 19 years. In a study of over 500 adults in the US, 99% of those younger than 60 years and 97% overall had protective tetanus antibody levels; comparable results were found for diphtheria. Other studies have shown no significant decrease in antibody levels with age, even in the absence of booster doses. The researchers emphasized that the goal of an immunization program is to prevent disease and not just to produce antibodies. Unlike tetanus, diphtheria is contagious; however, herd immunity remains strong in the absence of adult booster shots. In 2022, the UK reported 73 cases of diphtheria among asylum-seeking immigrants, the same number as that reported over the previous 20 years. None of the healthcare workers were infected. UK health officials concluded that the existing vaccination coverage was sufficient to prevent the spread of diphtheria and that the risk to the general population remained low.
Yahoo
19 hours ago
- Yahoo
Tensive appoints medical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market
Has more than 30 years of experience bringing innovations to market, including one of the world's first drug-eluting coronary stents at Angiotech Pharma Appointment adds world-class capabilities to Tensive as the company approaches pivotal clinical trial milestones Pivotal trial may enable European and U.S. commercialization of Tensive's innovative bioresorbable REGENERA™ and SOFTAG™ devices for breast reconstruction and tissue marking Tensive published positive first impressions from pivotal trial in April, and from first-in-human trial in 2023 Milan, Italy – August 5, 2025 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company, and the developer of REGENERA™ and SOFTAG™ bioresorbable scaffolds for breast reconstruction and tissue marking, has appointed Bill Hunter, MD, as Chairman of its Board of Directors. Dr. Hunter brings more than 30 years of leadership in the medical technology and life sciences sectors. His appointment reflects Tensive's focus on strengthening its governance and expanding its global network as it accelerates toward pivotal clinical milestones and commercialization in the U.S. and Europe. Dr. Hunter is the founder and CEO of Canary Medical, a medical data company developing implantable sensor technology. Previously, he founded Angiotech Pharmaceuticals, where he led the development of one of the world's first drug-eluting coronary stents, a multi-billion-dollar innovation that transformed interventional cardiology. 'It's a great honor and validation of the medical potential of Tensive's advanced biomaterials that Bill has accepted to lead our board of directors. His track record of successfully guiding pioneering technologies from concept to commercialization is unmatched,' said Sanjay Kakkar, Chief Executive Officer of Tensive. 'Bill's strategic insights and industry perspectives will be crucial advantages as we complete registrational studies and advance our first device into regulatory processes for marketing approval and commercialization in the U.S. and Europe.' Tensive's innovative polymeric bioresorbable scaffolds allow a natural, non-invasive, permanent and safe solution for breast reconstruction during lumpectomy. In addition, they enable precision tissue marking, demarcating the affected area to direct more targeted radiotherapy and improve imaging accuracy during surveillance and follow-up. 'I am truly excited to join Tensive at such a pivotal moment in its journey,' said Bill Hunter, MD, Chairman of the Tensive Board of Directors. 'In addition to being impressed by the leadership, I became convinced that this was an exceptional opportunity after reviewing the recently published interim data from the ongoing pivotal study of REGENERA™, as well as the excellent long-term follow-up data from the first-in-human clinical trial. The enthusiasm expressed by the key opinion leaders involved with the clinical studies further confirmed my impression of the data. I look forward to supporting Sanjay and his experienced team at Tensive as they bring REGENERA™ and SOFTAG™ to the market.' REGENERA™ / SOFTAG™ advanced biomaterial is a bioresorbable implant designed to be placed during lumpectomy surgery. The bioresorbable medical device is gradually absorbed by the body and enables the patient's own tissue to regrow in the area it fills. The result is breast restoration composed of natural tissue that preserves the patient's original breast shape and feel, yet is clearly differentiated from surrounding tissues on imaging, supporting more targeted delivery of radiotherapy and more accurate monitoring for potential recurrence. The biomaterial used in REGENERA™ and SOFTAG™ resembles a sponge with a fine scaffold matrix; its placement during the lumpectomy surgery is a one-step, minimally invasive, rapid and easy-to-adopt procedure. Currently, patients undergoing benign and malignant lumpectomy do not typically receive cosmetic intervention to prevent breast disfigurement, which can be psychologically devastating. Of the 2.1 million lumpectomies performed worldwide each year, 1.9 million are not reconstructed, constituting a sizeable unmet clinical need [1]. Despite the psychological impact of breast disfigurement following lumpectomy, more common cosmetic surgery options are rarely used, because they entail invasive and complex procedures that often fail to achieve the desired outcome. Preliminary data from the first 16 patients in Tensive's ongoing multi-center pivotal trial in 94 patients undergoing malignant lumpectomy were published in Updates in Surgery in April 2025, with investigators writing: 'In conclusion, we are convinced that REGENERA™ could represent a great innovation in breast oncological surgery, representing a possible alternative to volume replacement with faster operative time, faster recovery, less morbidity, and good patient satisfaction [2].' These results followed the publication in Breast Cancer in 2023 of six-month follow-up data from five patients in a first-in-human trial that demonstrated positive outcomes in terms of both safety and performance, leading the clinical investigators who authored the paper to conclude that the data were 'paving the way to an innovative approach with a potential remarkable impact on clinical application of tissue engineering [3].' [1] Analysis based on estimates from the International Society of Aesthetic Plastic Surgery (ISAPS), Breast Cancer Research Foundation (BCRF), the American College of Surgeons (ACS), the World Health Organization (WHO) and Global Market Insights.[2] A.V.E. Lisa et al. Updates in Surgery Apr 2025. Mariniello et al. Breast Cancer 2023. S.r.l. ( is a clinical-stage advanced biomaterials medical device company developing bioresorbable polymeric scaffolds for breast reconstruction and tissue marking. Its patented REGENERA™ biomimetic scaffold is designed to allow regeneration of a patient's own breast tissue to create natural, safe, and lasting reconstruction for patients recovering from lumpectomy or undergoing cosmetic procedures, while its SOFTAG™ precision tissue marking device enables more targeted delivery of radiotherapy and increases the accuracy of surveillance and follow-up. Tensive's mission is to improve clinical outcomes and the quality of life for women worldwide through accessible, innovative, and sustainable solutions. For more information please contact: Tensive Srl Cohesion Bureau media@ Italian and international media & investorsGiovanni Ca' Zorzitensive@ 7 8467 0727 Attachment 20250805 Tensive PR Bill Hunter appointment (final)Error in retrieving data Sign in to access your portfolio Error in retrieving data
